The strategic dialogue on tobacco harm reduction: A vision and blueprint for action in the US

Tobacco Control

Volumn 18, Issue 4, 2009, Pages 324-332

  Zeller, Mitchell ^a   Hatsukami, Dorothy ^a  

^a PINNEY ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; HARM REDUCTION; HEALTH CARE POLICY; HUMAN; METHODOLOGY; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; UNITED STATES;

HARM REDUCTION; HEALTH POLICY; HUMANS; SMOKING; SMOKING CESSATION; TOBACCO, SMOKELESS; UNITED STATES;

EID: 65549108868     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tc.2008.027318     Document Type: Article

References (71)

1. CDC. Cigarette smoking among adults - United States, 1995. MMWR Morb Mortal Wkly Rep 1997;46:1217-20.
2. CDC. Cigarette smoking among adults - United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:1157-61.
3. Stratton K, Shetty P, Wallace R, et al. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington, DC, USA: Institute of Medicine/National Academy Press, 2001:6.
4. Reuter P, Caulkins JP. Redefining the goals of national drug policy: recommendations from a working group. Maer J Public Health 1995;85:1059-63.
5. Marlatt GA. Harm reduction: come as you are. Addict Behav 1996;21:779-88.
6. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. Tob Control 2005;14:161-5.
7. Royal College of Physicians. Harm reduction in nicotine addiction. Helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London, UK: Royal College of Physicians, 2007.
8. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13. Bethesda, Maryland, USA: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2001.
9. Parascandola M. Lessons from the history of tobacco harm reduction: The National Cancer Institute's Smoking and Health Program and the "less hazardous cigarette". Nicotine Tob Res 2005;7:779-89.
10. Federal Trade Commission. Cigarette report for 2004 and 2005. Washington, DC, USA: Federal Trade Commission, 2007.
11. World Health Organization. Framework Convention on Tobacco Control. Geneva, Switzerland: WHO Document Production Services, 2005: article 9-11.
12. Family Smoking Prevention and Tobacco Control Act. Senate Bill 625; House of Representatives Bill 1108 (2007).
13. Bonnie RJ, Stratton K, Wallace RB. Ending the tobacco problem. A blueprint for the nation. Washington, DC, USA: National Academies Press, 2007.
14. Hatsukami D, Joseph AM, LeSage M, et al. Developing the science base for reducing tobacco harm. Nicotine Tob Res 2007;9(Suppl 4):S537-53.
15. Joseph AM, Hennrikus D, Thoele MJ, et al. Tobacco control leaders' perceptions of harm reduction. Tob Control 2004;13:108-13.
16. Martin EG, Warner KE, Lantz PM. Tobacco harm reduction: what do the experts think? Tob Control 2004;13:123-8.
17. Chapman S. Public health advocacy and tobacco control. Making smoking history. Oxford, UK: Blackwell Publishing, 2007.
18. Hammond D, Fong GT, Cummings KM, et al. Cigarette yields and human exposure: a comparison of alternative testing regimens. Cancer Epidemiol Biomarkers Prev 2006;15:1495-501.
19. Hatsukami D, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006;8:600-22.
20. Hatsukami D, Hecht SS. Hope or hazard? What research tells us about "potentially reduced-exposure" tobacco products. Minneapolis, Minnesota, USA: University of Minnesota Transdisciplinary Tobacco Use Research Center, 2005.
21. Hatsukami D, Ebbert JO, Feuer RM, et al. Changing smokeless tobacco products: new tobacco delivery systems. Am J Prev Med 2007;33(Suppl):S368-78.
22. Breland AB, Acosta MC, Eissenberg T. Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance. Tob Control 2003;12:317-21.
23. Breland AB, Kleykamp BA, Eissenberg T. Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine Tob Res 2006;8:727-38.
24. Hughes JR, Hecht SS, Carmella SG, et al. Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tob Control 2004;13:175-9.
25. Hatsukami D, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst 2004;96:844-52.
26. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 1994;331:123-5.
27. Benowitz NL, Jacob P 3rd, Herrera B. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 2006;80:703-14.
28. Benowitz NL, Hall SM, Stewart S, et al. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev 2007;16:2479-85.
29. Henningfield JE, Benowitz NL, Slade J, et al. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control 1998;7:281-93.
30. Roethig HJ, Kinser RD, Lau RW, et al. Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. J Clin Pharmacol 2005;45:133-45.
31. Roethig HJ, Zedler BK, Kinser RD, et al. Short-term clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. J Clin Pharmacol 2007;47:518-30.
32. Roethig HJ, Feng S, Liang Q, et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol 2008;48:580-91.
33. Frost-Pineda K, Zedler BK, Oliveri D, et al. Short-term clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul Toxicol Pharmacol 2008;52:104-10.
34. Stewart JC, Hyde RW, Boscia J, et al. Changes in markers of epithelial permeability and inflammation in chronic smokers switching to a nonburning tobacco device (Eclipse). Nicotine Tob Res 2006;8:773-83.
35. Hatsukami D, Lemmonds C, Tomar SL. Smokeless tobacco use: harm reduction or induction approach? Prev Med 2004;38:309-17.
36. Savitz DA, Meyer RE, Tanzer JM, et al. Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health 2006;96:1934-9.
37. Hecht SS, Carmella SG, Murphy SE, et al. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev 2007;16:1567-72.
38. Stepanov I, Jensen J, Hatsukami D, et al. Tobacco-specific nitrosamines in new tobacco products. Nicotine Tob Res 2006;8:309-13.
39. Stepanov I, Hecht SS, Ramakrishnan S, et al. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int J Cancer 2005;116:16-19.
40. Mendoza-Baumgart MI, Tulunay OE, Hecht SS, et al. Pilot study on lower nitrosamine smokeless tobacco products compared to medicinal nicotine. Nicotine Tob Res 2007;9:1309-23.
41. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. Lyon, France: IARC, 2007.
42. Rodu B. An alternative approach to smoking control. Am J Med Sci 1994;308:32-4.
43. Accortt NA, Waterbor JW, Beall C, et al. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol 2002;156:730-7.
44. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003;12:349-59.
45. Furberg H, Lichtenstein P, Pedersen NL, et al. Cigarettes and oral snuff use in Sweden: Prevalence and transitions. Addiction (Abingdon) 2006;101:1509-15.
46. Gartner CE, Hall WD, Vos T, et al. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007;369:2010-14.
47. Tomar SL. Epidemiological perspective on smokeless tobacco marketing and population harm. Am J Prev Med 2007;33:S387-97.
48. Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007;16:22-8.
49. Benowitz NL. Snuff, nicotine and cardiovascular disease: implications for tobacco control. J Am Coll Cardiol 1999;34:1791-3.
50. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91-111.
51. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J 1998;53(Suppl):75-114.
52. Russell MA. The future of nicotine replacement. Br J Addict 1991;86:653-8.
53. Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control 2008;17:132-41.
54. Ashley DL, Beeson MD, Johnson DR, et al. Tobacco-specific nitrosamines in tobacco from U.S. brand and non-U.S. brand cigarettes. Nicotine Tob Res 2003;5:323-31.
55. Hatsukami D, Ebbert JO, Anderson A, et al. Smokeless tobacco brand switching: a means to reduce toxicant exposure? Drug Alcohol Depend 2007;87:217-24.
56. US Department of Health & Human Services. The health consequences of smoking: nicotine and addiction. A report of the Surgeon General. Washington, DC, USA: US Department of Health & Human Services, 1988.
57. Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. BMJ 1976;1:1430-3.
58. Connolly GN, Alpert HR, Wayne GF, et al. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997-2005. Tob Control 2007;16:e5.
59. Henningfield JE, Benowitz NL, Connolly GN, et al. Reducing tobacco addiction through tobacco product regulation. Tob Control 2004;13:132-5.
60. Shiffman S, Pillitteri JL, Burton SL, et al. Smoker and ex-smoker reactions to cigarettes claiming reduced risk. Tob Control 2004;13:78-84.
61. Shiffman S, Jarvis MJ, Pillitteri JL, et al. UK smokers' and ex-smokers' reactions to cigarettes promising reduced risk. Addiction (Abingdon) 2007;102:156-60.
62. Cummings KM, Hyland A, Giovino GA, et al. Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob Res 2004;6(Suppl 3):S333-40.
63. Cohen JB. Smokers' knowledge and understanding of advertised tar numbers: health policy implications. Am J Public Health 1996;86:18-24.
64. Etter JF, Kozlowski LT, Perneger TV. What smokers believe about light and ultralight cigarettes. Prev Med 2003;36:92-8.
65. Kozlowski LT, Goldberg ME, Yost BA, et al. Smokers' misperceptions of light and ultra-light cigarettes may keep them smoking. Am J Prev Med 1998;15:9-16.
66. Shiffman S, Pillitteri JL, Burton SL, et al. Smokers' beliefs about "Light" and "Ultra Light" cigarettes. Tob Control 2001;10(Suppl 1):i17-23.
67. Hatsukami D, Giovino GA, Eissenberg T, et al. Methods to assess potential reduced exposure products. Nicotine Tob Res 2005;7:827-44.
68. French SA. Pricing effects on food choices. J Nutr 2003;133:S841-3.
69. Kozlowski LT. Harm reduction, public health, and human rights: smokers have a right to be informed of significant harm reduction options. Nicotine Tob Res 2002;4(Suppl 2):S55-60.
70. Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res 2004;6(Suppl 3):S303-10.
71. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res 2006;8:435-46.